You have read all your free articles, to continue reading subscribe to read the rest of this content.
Follicum has announced that data from studies on human Langerhans islets have shown positive effects on insulin release in line with the previously reported results on beta cells isolated from animals. The studies were performed through two different collaborations, one with Lund University and oAlready a subscriber Login You have…
AstraZeneca and MSD have announced positive results from the Phase III PAOLA-1 trial in women with advanced ovarian cancer. The trial, in the 1st-line maintenance setting, compared Lynparza(olaparib) added to standard-of-care (SoC) bevacizumab vs. bevacizumab alone in women with or without BRCA gAlready a subscriber Login You have read all…
Cantargia has announced that its research platform CANxx has progressed with the start of a drug development project, CAN10. The project originates from inhibition of three inflammatory cytokine systems (IL-1, IL-33 and IL-36) by antibody targeting of interleukin 1 receptor accessory protein (IL1Already a subscriber Login You have read all…
Oncopeptides has announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating the efficacy and safety of a triple combination therapy with melflufen plus dexamethasone and subcutaneous daratumumab compared to daratumumab alone. The phase 3 LIGHTHOUSE study is a randAlready a subscriber Login You have…
